National Institute for Health & Care Excellence

Crizotinib
Sept 2016
(first line)

Ceritinib

Jun 2018

(after Crizotinib)

Lorlatinib

May 2020

(previously treated)

Cancer
Recognition
& Referral

Crizotinib
Dec 2016
(previously treated)

Alectinib

Aug 2018

(first line)

Brigatinib

Nov 2020

(first line)

Lung Cancer

Diagnosis &

Management

Ceritinib

Jan 2018

(first line)

Brigatinib

March 2019

(after Crizotinib)

Brigatinib

(after Cerit/Alect)

Suspended

Lorlatinib approved for 1st line use in Scotland March 2022